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With more than 500 identified constituents Cannabis sativa L. (hemp, Cannabaceae) is 
one of the chemically most elucidated plant. Delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) are the cannabinoids in focus whereas mainly terpenoids are part of 
the non-cannabinoid fraction. Most of the pharmacological effects of cannabis are due 
to interference with the endocannabinoid system. Despite a plethora of therapeutic 
effects cannabis and cannabinoids should not be classified as panacea. The still existing 
discrepancy between empirical (what patients claim from self-treatment) and 
evidence-based knowledge (what doctors and pharmacists know by education and 
experience in practice) requires a better interdisciplinary scientific bridging and clinical 
trials targeting the most promising indications. However, research and use of cannabis 
and cannabinoid-based medications pose different challenges, such as its complex 
pharmacokinetics, ideal formulation, safe application mode, and supply. 
Controversially debated are pros and cons of the two therapeutic options, i.e. «full 
spectrum» (e.g. cannabis flower extracts) and «single compound» (isolated or 
synthesized pure THC, CBD). Pharmacopoeia monographs to define quality and 
industry standards, and appropriate regulatory and legal measure are needed to 
facilitate the controlled access to medical cannabis, a powerful therapeutic tool still 
discriminated and ignored by too many countries and medical professionals. 
  
